PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) will report its Q3 2023 financial results and operational highlights on November 8, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 8, 2023
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BIbd0a9baa57b1427e809302152ba58bd3
Webcast:	https://edge.media-server.com/mmc/p/r9ot5d24

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

FAQ

When will PolyPid report its Q3 2023 financial results?

PolyPid will report its Q3 2023 financial results on November 8, 2023.

What is the stock symbol for PolyPid?

The stock symbol for PolyPid is PYPD.

What time will the conference call and webcast start?

The conference call and webcast will start at 8:30 AM Eastern Time.

How can I listen to the conference call?

You can listen to the conference call via the webcast using the following link: https://edge.media-server.com/mmc/p/r9ot5d24.

Is there a recommended time to register for the conference call?

PolyPid suggests registering a minimum of 5 minutes before the start of the call to ensure you are connected.

Will there be an opportunity to ask questions during the conference call?

Yes, participants can ask questions during the conference call.

Where can I find the conference call dial-in information?

The conference call dial-in information can be found at this link: https://register.vevent.com/register/BIbd0a9baa57b1427e809302152ba58bd3